Symbol="BLTE"
AssetType="Common Stock"
Name="Belite Bio Inc ADR"
Description="Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, is engaged in the research and development of novel therapies targeting age-related atrophic macular degeneration and autosomal recessive stargardt diseases. The company is headquartered in San Diego, California."
CIK="1889109"
Exchange="NASDAQ"
Currency="USD"
Country="USA"
Sector="LIFE SCIENCES"
Industry="PHARMACEUTICAL PREPARATIONS"
Address="12750 HIGH BLUFF DRIVE SUITE 475, SAN DIEGO, CA, CA"
FiscalYearEnd="December"
LatestQuarter="2023-06-30"
MarketCapitalization="656154000"
EBITDA="-18576500"
PERatio="None"
PEGRatio="None"
BookValue="1.412"
DividendPerShare="0"
DividendYield="0"
EPS="-0.76"
RevenuePerShareTTM="0"
ProfitMargin="0"
OperatingMarginTTM="0"
ReturnOnAssetsTTM="-0.256"
ReturnOnEquityTTM="-0.712"
RevenueTTM="0"
GrossProfitTTM="0"
DilutedEPSTTM="-0.76"
QuarterlyEarningsGrowthYOY="0"
QuarterlyRevenueGrowthYOY="0"
AnalystTargetPrice="45.67"
TrailingPE="-"
ForwardPE="-"
PriceToSalesRatioTTM="-"
PriceToBookRatio="15.48"
EVToRevenue="-"
EVToEBITDA="-91.18"
Beta="None"
num_52WeekHigh="39.85"
num_52WeekLow="11"
num_50DayMovingAverage="16.59"
num_200DayMovingAverage="26.34"
SharesOutstanding="27226300"
DividendDate="None"
ExDividendDate="None"
symbol="BLTE"
open="20.54"
high="24.50"
low="20.54"
price="24.10"
volume="91310.00"
latest_trading_day="2023-07-28"
previous_close="20.55"
change="3.55"
change_percent="17.2749%"
aroon_positive_momentum_days="0"
aroon_negative_momentum_days="90"
trend_strength="Absent or Weak Trend"
buying_signal="Weak Sell Signal"
volume_analysis="Target Volume"
value_analysis="Expected Range"
Aroon_change="FALSE"
Aroon_momentum="10"
Volume_recent_avg="38258"
Change_recent_avg="-0.12"
Delta_recent_avg="1.42"
Variance_recent_avg="0.71"
Change_ratio_recent_avg="-0.53"
RSI_change="FALSE"
ADX_change="FALSE"

event="FALSE"
Aroon_signal="negative"
Aroon_change="FALSE"
Aroon_momentum_positive="10"
Aroon_momentum_negative="90"
image_negative_thumbnail_id_1="1126"
image_negative_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0159.jpeg"
image_negative_thumbnail_id_2="1097"
image_negative_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Negative_Landscape_0130.jpeg"
image_neutral_thumbnail_id_1="549"
image_neutral_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0050.jpeg"
image_neutral_thumbnail_id_2="563"
image_neutral_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Neutral_Landscape_0036.jpeg"
image_positive_thumbnail_id_1="956"
image_positive_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0118.jpeg"
image_positive_thumbnail_id_2="699"
image_positive_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Positive_Landscape_0009.jpeg"
image_professor_thumbnail_id_1="1182"
image_professor_url_1="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0016.jpeg"
image_professor_thumbnail_id_2="1174"
image_professor_url_2="https://hehge.com/wp-content/uploads/sites/16/2023/06/MI_Finance_Professor_Landscape_0008.jpeg"
